A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer
| Autor: | Andrew C Hindley, Christian M. Kurbacher, Ian A. Cree, Sharon Love, Alan Lamont |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Combination therapy medicine.medical_treatment Antineoplastic Agents Adenocarcinoma Disease-Free Survival law.invention Randomized controlled trial law Internal medicine medicine Tumor Cells Cultured Humans Pharmacology (medical) Prospective Studies Practice Patterns Physicians' Prospective cohort study Pharmacology Ovarian Neoplasms Chemotherapy business.industry Hazard ratio Middle Aged medicine.disease Confidence interval Surgery Drug Resistance Neoplasm Female Cisplatin Drug Screening Assays Antitumor Neoplasm Recurrence Local Ovarian cancer business Chemosensitivity assay |
| Zdroj: | Anti-cancer drugs. 18(9) |
| ISSN: | 0959-4973 |
| Popis: | The primary aim of this randomized trial was to determine response rate and progression-free survival following chemotherapy in patients with platinum-resistant recurrent ovarian cancer, who had been treated according to an ATP-based tumour chemosensitivity assay in comparison with physician's choice. A total of 180 patients were randomized to assay-directed therapy (n=94) or physician's-choice chemotherapy (n=86). Median follow-up at analysis was 18 months. Response was assessable in 147 patients: 31.5% achieved a partial or complete response in the physician's-choice group compared with 40.5% in the assay-directed group (26 versus 31% by intention-to-treat analysis respectively). Intention-to-treat analysis showed a median progression-free survival of 93 days in the physician's-choice group and 104 days in the assay-directed group (hazard ratio 0.8, 95% confidence interval 0.59-1.10, not significant). No difference was seen in overall survival between the groups, although 12/39 (41%) of patients who crossed over from the physician's-choice arm obtained a response. Increased use of combination therapy was seen in the physician's-choice arm during the study as a result of the observed effects of assay-directed therapy in patients. Patients entering the physician's-choice arm of the study during the first year did significantly worse than those who entered in the subsequent years (hazard ratio 0.44, 95% confidence interval 0.2-0.9, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|